Please use this identifier to cite or link to this item:
Title: Extracellular Vesicle-Based Therapeutics for Heart Repair
Authors: Saludas, Laura
Oliveira, Cláudia C.
Roncal, Carmen
Ruiz-Villalba, Adrián
Prósper, Felipe
Garbayo, Elisa
Blanco-Prieto, María J.
metadata.dc.contributor.authoraffiliation: [Saludas,L; Garbayo,E; Blanco-Prieto,MJ] Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain. [Saludas,L; Roncal,C; Prósper,F; Garbayo,E; Blanco-Prieto,MJ] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. [Oliveira,CC; Ruiz-Villalba,A] Department of Animal Biology, Institute of Biomedicine of Málaga (IBIMA), Faculty of Science, University of Málaga, Málaga, Spain. [Oliveira,CC; Ruiz-Villalba,A] Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain. [Roncal,C] Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, CIMA, University of Navarra, Pamplona, Spain. [Roncal,C] Centro de Investigación Biomédica en Red (CIBERCV), Carlos III Institute of Health, Madrid, Spain. [Prósper,F] Program of Regenerative Medicine, CIMA, University of Navarra, Pamplona, Spain. [Prósper,F] Cell Therapy Area and Haematology Department, Clínica Universidad de Navarra, Pamplona, Spain. [Prósper,F] Centro de Investigación Biomédica en Red (CIBERONC), Carlos III Institute of Health, Madrid, Spain.
Keywords: Cardiovascular diseases;Myocardial infarction;Cardiac repair;Extracellular vesicles;Exosomes;Drug delivery;Cargo loading;Targeting;Enfermedades cardiovasculares;Infarto del miocardio;Vesículas extracelulares;Exosomas;Sistemas de liberación de medicamentos
metadata.dc.subject.mesh: Medical Subject Headings::Diseases::Cardiovascular Diseases
Medical Subject Headings::Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction
Medical Subject Headings::Anatomy::Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Cytoplasmic Vesicles::Transport Vesicles::Exosomes
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy
Medical Subject Headings::Diseases::Cardiovascular Diseases::Heart Diseases
Medical Subject Headings::Phenomena and Processes::Metabolic Phenomena::Metabolism::Biological Transport
Medical Subject Headings::Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Communication
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Delivery Systems
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy
Issue Date: 25-Feb-2021
Publisher: MDPI
Citation: Saludas L, Oliveira CC, Roncal C, Ruiz-Villalba A, Prósper F, Garbayo E, et al. Extracellular Vesicle-Based Therapeutics for Heart Repair. Nanomaterials. 2021 Feb 25;11(3):570.
Abstract: Extracellular vesicles (EVs) are constituted by a group of heterogeneous membrane vesicles secreted by most cell types that play a crucial role in cell-cell communication. In recent years, EVs have been postulated as a relevant novel therapeutic option for cardiovascular diseases, including myocardial infarction (MI), partially outperforming cell therapy. EVs may present several desirable features, such as no tumorigenicity, low immunogenic potential, high stability, and fine cardiac reparative efficacy. Furthermore, the natural origin of EVs makes them exceptional vehicles for drug delivery. EVs may overcome many of the limitations associated with current drug delivery systems (DDS), as they can travel long distances in body fluids, cross biological barriers, and deliver their cargo to recipient cells, among others. Here, we provide an overview of the most recent discoveries regarding the therapeutic potential of EVs for addressing cardiac damage after MI. In addition, we review the use of bioengineered EVs for targeted cardiac delivery and present some recent advances for exploiting EVs as DDS. Finally, we also discuss some of the most crucial aspects that should be addressed before a widespread translation to the clinical arena.
metadata.dc.identifier.doi: 10.3390/nano11030570
ISSN: 2079-4991 (Online)
Appears in Collections:01- Artículos - BIONAND - Centro Andaluz de Nanomedicina y Biotecnología
01- Artículos - IBIMA. Instituto de Investigación Biomédica de Málaga

Files in This Item:
File Description SizeFormat 
Saludas_ExtracellularVesicleBased.pdfArtículo publicado2,71 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons